ARIKACE Demonstrates Sustained Benefit In The Treatment Of Cystic Fibrosis Patients WInformation on ARIKACE Demonstrates Sustained Benefit In The Treatment Of Cystic Fibrosis Patients W under Lung & Respiratory section of the Health Articles & Reviews; Transave, Inc., reported interim results from a multi-cycle Phase II open label clinical trial in cystic fibrosis (CF) patients on its lead investigational drug, ARIKACE ... |
 |
|
ARIKACE Demonstrates Sustained Benefit In The Treatment Of Cystic Fibrosis Patients W
by Ila_Wooten 06-19-2010, 02:00 PM
Transave, Inc., reported interim results from a multi-cycle Phase II open label clinical trial in cystic fibrosis (CF) patients on its lead investigational drug, ARIKACE (liposomal amikacin for inhalation). The data indicated that ARIKACE, delivered once daily for 28 consecutive days followed by 56 days off-treatment for four cycles demonstrated statistically significant improvement in lung ...
More... |
Views 87
Comments 0
|
|
| Bookmarks |
| Currently Active Users Viewing This Article: 1 (0 members and 1 guests) | |
| Article Tools | |
| Display Modes | |
|
|
 |  |  |  |
 |  |  |  |
 |  |  |  |
 |  |  |  |
 |  |  |  |
Linear Mode
